1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Pituitary ACTH Hypersecretion (Cushing%s Disease) - Pipeline Review, H1 2015

Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H1 2015’, provides an overview of the Pituitary ACTH Hypersecretion (Cushing's Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing's Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pituitary ACTH Hypersecretion (Cushing's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pituitary ACTH Hypersecretion (Cushing's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pituitary ACTH Hypersecretion (Cushing's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing's Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing's Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Pituitary ACTH Hypersecretion (Cushing%s Disease) - Pipeline Review, H1 2015
Table of Contents
Introduction 7
Global Markets Direct Report Coverage 7
Pituitary ACTH Hypersecretion (Cushing's Disease) Overview 8
Therapeutics Development 9
Pipeline Products for Pituitary ACTH Hypersecretion (Cushing's Disease) - Overview 9
Pipeline Products for Pituitary ACTH Hypersecretion (Cushing's Disease) - Comparative Analysis 10
Pituitary ACTH Hypersecretion (Cushing's Disease) - Therapeutics under Development by Companies 11
Pituitary ACTH Hypersecretion (Cushing's Disease) - Therapeutics under Investigation by Universities/Institutes 12
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Pituitary ACTH Hypersecretion (Cushing's Disease) - Products under Development by Companies 17
Pituitary ACTH Hypersecretion (Cushing's Disease) - Products under Investigation by Universities/Institutes 18
Pituitary ACTH Hypersecretion (Cushing's Disease) - Companies Involved in Therapeutics Development 19
Alder Biopharmaceuticals Inc. 19
Corcept Therapeutics Incorporated 20
Cortendo AB 21
ElexoPharm GmbH 22
Ipsen S.A. 23
Isis Pharmaceuticals, Inc. 24
Novartis AG 25
Orphagen Pharmaceuticals, Inc. 26
Pfizer Inc. 27
Pituitary ACTH Hypersecretion (Cushing's Disease) - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
ALD-1613 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
AT-814 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
ATR-101 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
DG-3173 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
ISIS-GCCRRx - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
ketoconazole - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
LCI-699 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
mifepristone - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
MPP-482 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
pasireotide LAR - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Peptides to Antagonize ACTH Receptor for Cushing's Syndrome - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Small Molecule to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Small Molecules to Inhibit Cortisol for Metabolic Disorders - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Pituitary ACTH Hypersecretion (Cushing's Disease) - Recent Pipeline Updates 58
Pituitary ACTH Hypersecretion (Cushing's Disease) - Dormant Projects 66
Pituitary ACTH Hypersecretion (Cushing's Disease) - Product Development Milestones 67
Featured News and Press Releases 67
Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting and Expo 67
Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014 67
Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014 67
Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014 67
Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting 68
Jun 19, 2014: New Research on Corcept's Korlym for Patients with Cushing's Syndrome to be Presented at ICE/ENDO 2014 68
Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing's Syndrome 70
Apr 10, 2012: Corcept Therapeutics Launches Korlym For Patients With Endogenous Cushing's Syndrome 70
Apr 09, 2012: Corcept Announces Publication Of Phase III Trial Results Of Korlym In Journal of Clinical Endocrinology and Metabolism 71
Mar 26, 2012: Corcept Selects PharmaForm As Primary Commercial Manufacturer For Korlym 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

List of Tables

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing's Disease), H1 2015 9
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing's Disease) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Comparative Analysis by Unknown Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Alder Biopharmaceuticals Inc., H1 2015 19
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Corcept Therapeutics Incorporated, H1 2015 20
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Cortendo AB, H1 2015 21
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by ElexoPharm GmbH, H1 2015 22
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Ipsen S.A., H1 2015 23
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 24
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Novartis AG, H1 2015 25
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 26
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Pfizer Inc., H1 2015 27
Assessment by Monotherapy Products, H1 2015 28
Number of Products by Stage and Target, H1 2015 30
Number of Products by Stage and Mechanism of Action, H1 2015 32
Number of Products by Stage and Route of Administration, H1 2015 34
Number of Products by Stage and Molecule Type, H1 2015 36
Pituitary ACTH Hypersecretion (Cushing's Disease) Therapeutics - Recent Pipeline Updates, H1 2015 58
Pituitary ACTH Hypersecretion (Cushing's Disease) - Dormant Projects, H1 2015 66

List of Figures

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing's Disease), H1 2015 9
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing's Disease) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 15
Assessment by Monotherapy Products, H1 2015 28
Number of Products by Top 10 Targets, H1 2015 29
Number of Products by Stage and Top 10 Targets, H1 2015 29
Number of Products by Top 10 Mechanism of Actions, H1 2015 31
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 31
Number of Products by Top 10 Routes of Administration, H1 2015 33
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 33
Number of Products by Top 10 Molecule Types, H1 2015 35
Number of Products by Stage and Top 10 Molecule Types, H1 2015 35

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.